Pneumonitis in an elderly Bangladeshi man

The incidence of primary varicella zoster virus infection (VZV) in young adults and pregnant women has risen in recent years and is accompanied by a greater risk of serious complications. VZV disease in the elderly usually presents as shingles, as a result of secondary reactivation of latent infection, and can be treated successfully with early antiviral therapy. We report a case of fatal primary infection in an elderly man.

A 66 year old Bangladeshi man with fibrosing alveolitis and non-insulin dependent diabetes mellitus was admitted to hospital with increasing shortness of breath for one week. He was a smoker and had been well controlled on 25 mg of prednisolone daily for the previous two months.

On admission he was febrile (38.5°C), tachypnoeic (50 breaths/minute), and hypotensive (blood pressure, 85/60 mm Hg), with severe mucosal candidiasis. An extensive maculopapular rash, present for three days, was noted and thought to be consistent with amoxicillin treatment, which had been started before admission. Coarse crepitations were heard throughout the chest, oxygen saturation was 80% on air, and blood gases showed type I respiratory failure (pH 7.3; partial CO\textsubscript{2} pressure, 4.8 kPa; partial O\textsubscript{2} pressure, 8.39 kPa; HC\textsubscript{O}\textsubscript{3}, 19.4 mmol/litre). Haemoglobin was 180 g/litre, white blood cell count was 8.5 × 10\textsuperscript{9}/litre, serum creatinine was 180 mmol/litre, and blood glucose was 22.2 mmol/litre. Chest x ray showed right mid zone consolidation (fig 1). Bronchopneumonia was diagnosed; intra-vacuolar cefotaxime, clari tromycin, and fluconazole were commenced. After consultation with the virologists the patient also received aciclovir (10 mg/kg) intravenously.

He required intubation, ventilation, and inotropic support within 14 hours of admission. He remained persistently hypoxic despite 100% oxygen, positive end expiratory pressure, inverse ratio ventilation, and nebulised prostacyclin. Oxygenation improved dramatically with prone ventilation. Renal replacement treatment was started on day 3. On day 4 the rash was noted to be vesicular. Skin scrapings and respiratory secretions were then examined for herpes simplex virus (HSV) and VZV by immunofluorescence (Dako, Ely, UK) and were positive for VZV. Subsequent enquiry did not reveal a chickenpox contact. VZV serology (Dade Behring, Deerfield, Illinois, USA) was positive for VZV IgM and negative for VZV IgG antibodies and a diagnosis of chickenpox was made. He received a single dose of normal immunoglobulin (Sandoglobulin; Novartis, Camberley, Surrey, UK; 200 mg/kg) and the aciclovir was continued for 14 days. Respiratory function gradually deteriorated despite 16 hours of prone ventilation each day and he died 23 days after admission.

VZV pneumonitis after primary infection is a severe disease with high mortality, especially in non-immune pregnant women, neonates, and the immunosuppressed. Smoking and previous treatment with steroids have been identified as independent risk factors. In the UK, primary disease in the elderly is a very unusual occurrence because there is almost universal seroconversion by early adulthood. In the tropics, seroconversion occurs at a later age, with seronegativity as high as 42% being found in rural Bangladeshi adults. It is interesting that although this patient had been resident in the UK for over 20 years he remained susceptible.

Intensive therapy unit (ITU) management of respiratory failure with ventilatory support is essential in varicella pneumonitis. Retrospective analysis of patients treated with aciclovir has shown some benefit of treatment, especially when instigated early, but there has been no randomised trial to date. High doses (10 mg/kg) are essential to obtain serum titres that are inhibitory to VZV (0.08–1.2 mg/litre). The use of steroids in varicella pneumonia is controversial, with one small trial showing a reduction in ITU and hospital stay, but no effect on overall mortality. Normal immunoglobulin (100–300 mg/kg) has also been given, with variable results.

Pneumonitis due to varicella zoster immunoglobulin (VZIG) has been successful in preventing or attenuating disease in non-immune contacts of primary cases after exposure. A live attenuated vaccine (Oka strain) has been tested in some countries, but is available on a named patient basis only in the UK.

This is the fourth fatal case of adult varicella pneumonitis we have seen in six years, and the second in an elderly Bangladeshi man taking steroids for lung disease. Although a characteristic chickenpox rash can precede the onset of pneumonitis by three to five days, our converse experience in these patients is that it may not be present or may be atypical. Diagnosis is often delayed and initial treatment may sometimes be inappropriate. Varicella is a preventable disease and consideration should now be given to the identification and vaccination of seronegative individuals at risk of severe infection.

D W WAREHAM
J BREUER
Department of Medical Microbiology, Barts and The London NHS Trust, London E1 1BB, UK
M T HEALY
D R GOLDHILL
Department of Intensive Care, Barts and The London NHS Trust, London E1 1BB, UK


Figure 1 Plain chest x ray taken on admission.
When should a coroner’s inquest be held? The Manchester guidelines for pathologists

I am grateful to Dr Roberts and colleagues for their important paper and argument to formulate guidelines on when to report a death to the coroner and decisions thereafter. The authors’ important implications for practitioners in primary and secondary care. One particular dilemma is when to discuss with the coroner what appears to be a natural death, where the cause is unknown or where the patient is well known to the practitioner, but has not consulted in the required preceding 14 days. This is compounded by the variation in attitudes of coroners and their officers to such discussions. It is indeed a “grey area” where standard guidelines are required for doctors and coroners so that it can be determined more precisely when necropsies and inquests are required. To facilitate this process, death certificates and the second part of cremation forms could comprise specific additional questions. These should ascertain the extent to which the certifying practitioner, and the independent practitioner in the case of a cremation, is aware of the patient’s medical history, and the information on previous treatments. This multiauthor review has 16 chapters, which should find its place in pharmacology departments and neurology libraries.

R ROBINSON


This multiauthor review has 16 chapters, broken down into sections on the physiology of chemokines, tumour infiltration by leucocytes, modulation of host response to cancer, chemokines and tumour growth and metastasis, associations with specific malignancies, and finally effects on stem cell proliferation. Authors are predominantly from US centres, with a scattering of Europeans.

I have to admit to finding this mostly hard going and, after starting off with good intentions and struggling through half of the book, it was laid aside as more easily digestible and clinically useful things usurped my attention. Half the problem is the multiplicity of cytokines, mostly with incomprehensible names, which makes it necessary for the non-specialist to keep referring back to the first chapter to have any idea about the remaining chapters. This is a fast moving field, so it is difficult to say what the value of this publication is except as a way mark for the long journey of discovery in cancer research.

There is little here for the working pathologist, but plenty for the chemokine and cancer immunology researcher. I doubt very much whether it will find a general market for interested non-specialists. Mainly one for the library!

G P SPICKETT

Book reviews


Valproate has been the subject of over 5000 publications. It was discovered accidentally: it was used as a vehicle for some water insoluble compounds under investigation and found to have an independent anticonvulsant effect. The first clinical reports appeared in 1964. It can justifiably claim its place in the “milestones in drug therapy” series. This book fulfils the main purpose of a monograph. The development, pharmacology, use, and side effects of this drug are all well covered and extensively referenced. Anyone wishing information on valproate would be unlucky indeed not to find it within these covers.

If I have a criticism it would be that the editor has not been strict enough with his contributors. Thus—for example, the chapter on toxicity is rather diffuse. The length of the chapter on the use of sodium valproate in headache (20 pages) seems disproportionate in that there are only four double blind, placebo controlled trials in the use of this drug in migraine.

However, these nitpicking criticisms do not detract from the value of this useful book, which should find its place in pharmacy departments and neurology libraries.

R ROBINSON

Correspondence, Book reviews, Calendar of events

R L TEN BERGE
J OUDJEANS
D P DUKERS
C L J MEIJER

Department of Pathology, University Hospital Vrije Universiteit, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands


The authors reply

Some years ago, and on the basis of no evidence whatsoever, we suspected that general practitioners were not interested in the outcomes of necropsies. However, and to our great satisfaction, a questionnaire study demonstrated that this view was completely wrong. Dr Charlton provides further support for the necropy from primary care, and our pleasure knows no bounds.

We fully support Dr Charlton’s suggestion that pathologists should talk to relatives, and we often do so, on an ad hoc basis, after inquests, etc. However, in most hospitals, including ours, there are not enough histopathologists to make routine interviews with relatives a realistic proposition. At the moment, we would prefer to keep this task to remain with general practitioners.2

Necropsies and inquests have many functions beyond simple confirmation or refutation of clinical diagnoses. We agree that they might be useful aimed at different targets, but we would take issue with Dr Charlton’s assertions that many necropsies could be avoided because the diagnosis can be made before death. Clinicians can make correct diagnoses in most cases, but discrepancy rates between clinical and postmortem diagnoses remain woefully high, even when the clinicians are confident about their diagnoses.3 Much might be said for a system where necropsies are only performed in cases where a death is unexpected, a situation which was fine except that much of the paediatric chapter was taken up with a description of different paediatric epilepsy syndromes; interesting and important information but not directly relevant. The length of the chapter on the use of sodium valproate in headache (20 pages) seems disproportionate in that there are only four double blind, placebo controlled trials in the use of this drug in migraine.

This is a fast moving field, so it is difficult to say what the value of this publication is except as a way mark for the long journey of discovery in cancer research.

There are many here for the working pathologist, but plenty for the chemokine and cancer immunology researcher. I doubt very much whether it will find a general market for interested non-specialists. Mainly one for the library!
Calendar of events

*Full details of events to be included should be sent to Maggie Butler, Technical Editor, *JCP*, The Cedars, 36 Queen Street, Castle Hedingham, Essex CO9 3HA, UK; email: maggiebutler@pilotree.prestel.co.uk*

**Professional Standards of Pathologists in a Modern NHS Pathology Service**
7 June 2001, Royal College of Pathologists, London, UK
*Further details:* Michelle Casey, Academic Activities Coordinator, 2 Carlton House Terrace, London SW1Y 5AF, UK. (Tel +44 020 7451 6700; fax +44 020 7451 6701; www.rcpath.org)

**Recent Advances in Genetics**
5 July 2001, Royal College of Pathologists, London, UK
*Further details:* Michelle Casey, Academic Activities Coordinator, 2 Carlton House Terrace, London SW1Y 5AF, UK. (Tel +44 020 7451 6700; fax +44 020 7451 6701; www.rcpath.org)

**BSCC Annual Scientific Meeting**
9–11 September 2001, Majestic Hotel, Harrogate, UK
*Further details:* BSCC Office, PO Box 352, Uxbridge UB10 9TX, UK. (Tel +44 01895 274020; fax +44 01895 274080; email lesley.couch@psilink.co.uk)

**Infectious Hazards of Donated Organs**
28 June 2001, Royal College of Pathologists, London, UK
*Further details:* Michelle Casey, Academic Activities Coordinator, 2 Carlton House Terrace, London SW1Y 5AF, UK. (Tel +44 020 7451 6700; fax +44 020 7451 6701; www.rcpath.org)

**41st St Andrew’s Day Festival Symposium on Therapeutics**
6–7 December 2001, Royal College of Physicians, Edinburgh, UK
*Further details:* Eileen Strawn, Symposium Coordinator. (Tel +44 0131 225 7324; fax +44 0131 220 4393; email 2.strawn@rcpe.ac.uk; website www.rcpe.ac.uk)

**Current Concepts in Surgical Pathology**
12–16 November 2001, The Four Seasons Hotel, Boston, Massachusetts, USA
*Further details:* Department of Continuing Education, Harvard Medical School, PO Box 825, Boston, MA 02117-0825. (Tel +1 617 432 1525; Fax +1 617 432 1562; email hms-cme@harvard.edu; web page http://www.med.harvard.edu/conted/)

---

**Pay per access**

For just US$25 you can have instant access to the whole website for 30 days. During this time you will be able to access the full text for all issues (including supplements) available. You will also be able to download and print any relevant pdf files for personal use, and take advantage of all the special features *Journal of Clinical Pathology* online has to offer.

[www.jclinpath.com](http://www.jclinpath.com)